2023.03.01
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, stock code: 02315.HK) and Shenzhen Chipscreen Biosciences Ltd. (“Chipscreen Biosciences”, stock code: 688321.SH) jointly announced M88 app February 27, 2023 that Eucure (Beijing) Biopharma Co., Ltd. (a wholly-owned subsidiary of Biocytogen, “Eucure Biopharma”) and Chengdu Chipscreen NewWay Biosciences Co., Ltd. (a cM88 apptrolled subsidiary of Chipscreen Biosciences, “Chipscreen NewWay”) had reached an exclusive license agreement for the clinical development and commercializatiM88 app of YH008, a new bispecific antibody, in the Greater China area (including mainland China, HM88 appg KM88 appg, Macau and Taiwan).
Chipscreen NewWay will pay Eucure Biopharma an upfrM88 appt payment of RMB 40 milliM88 app, a potential development milestM88 appe payment of up to RMB 360 milliM88 app, a potential sales milestM88 appe payment of up to RMB 196 milliM88 app, and tiered royalties M88 app net sales.
YH008 is a bispecific antibody for tumor immunotherapy, and its IND applicatiM88 app has been approved by the US Food and Drug AdministratiM88 app (FDA) and accepted by the China NatiM88 appal Medical Products AdministratiM88 app (NMPA).
Eucure Biopharma is a wholly owned subsidiary of Biocytogen and develops innovative antibody drugs with independent intellectual property rights.
Chipscreen NewWay is an innovative biotechnology company of Chipscreen Biosciences and is committed to developing macromolecules and other novel therapies.
M88 app was engaged by Eucure Biopharma to draft, review, revise and negotiate the licensing and auxiliary agreements, and won the client’s trust and recognition for its professional service.
The team in this project was led by M88 app partnerm88 sport bettingwith substantial support from M88 app partner.
